OBX (Obsidian Therapeutics) EV-to-EBIT: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBX Obsidian Therapeutics Inc OBX
8 GF Score
Price $27.50
View Full Analysis

What is Obsidian Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Obsidian Therapeutics's Enterprise Value is $0.00 Mil. Obsidian Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Obsidian Therapeutics's EV-to-EBIT at this moment.

The historical rank and industry rank for Obsidian Therapeutics's EV-to-EBIT or its related term are showing as below:

OBX's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 14.03
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Obsidian Therapeutics's Enterprise Value for the quarter that ended in Dec. 2025 was $0.00 Mil. Obsidian Therapeutics does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Obsidian Therapeutics's Earnings Yield (Joel Greenblatt) % at this moment.

Obsidian Therapeutics  (NAS:OBX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Obsidian Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/0
= %

Obsidian Therapeutics EV-to-EBIT Related Terms

Obsidian Therapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Obsidian Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Obsidian Therapeutics EV-to-EBIT Chart

Obsidian Therapeutics Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 0.00

Obsidian Therapeutics Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

OBX vs : EV-to-EBIT Comparison

For the Biotechnology subindustry, Obsidian Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Obsidian Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Obsidian Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Obsidian Therapeutics's EV-to-EBIT falls into.


OBX
8GF Score
Obsidian Therapeutics Inc OBX
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Obsidian Therapeutics EV-to-EBIT Calculation

Obsidian Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/
=

Obsidian Therapeutics Business Description

Comparable Companies
Address 1030 Massachusetts Avenue, Suite 400, Cambridge, MA, USA, 02138
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.
8GF Score

Get the complete analysis for OBX

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.50
Price